-
Innovation Ranking
NewInnovation Ranking – SBI Holdings Inc
SBI Holdings Inc (SBI Holdings) is an internet-based financial solutions provider. It offers a range of financial and asset management services; and biotechnology-related solutions through its subsidiaries. Its financial solutions include securities brokerage; retail and business banking; investment banking; and life, non-life, and short-term insurance. The company’s asset management consists of fund and asset management, venture capital funds, and buyout investments. Through its biotechnology-related business, SBI Holdings carries out the distribution and development of health foods, cosmetics containing 5-aminolevulinic acid;...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SBI-100 in Ocular Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SBI-100 in Ocular Hypertension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SBI-100 in Ocular Hypertension Drug Details: NB-1111 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SBI-100 in Open-Angle Glaucoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SBI-100 in Open-Angle Glaucoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SBI-100 in Open-Angle Glaucoma Drug Details: NB-1111 is under development for the...
-
Company Insights
Innovation and Patenting activity of SBI Holdings Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of SBI Holdings Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Analyst Opinions
Immersive Enterprise – Sector Impact of Alternative Reality Technologies
Immersive Enterprise – Sector Impact of Alternative Reality Technologies Report Overview The immersive platform landscape is being shaped by a host of convergent trends, such as advanced hardware, 5G roll-out, cloud computing, miniaturization, and collaborative features among others. This report serves as an invaluable resource for gaining insights into how the adoption of immersive platforms not only enhances user experiences but also cultivates customer-centric strategies. In addition, the report highlights advantages, such as fostering greater engagement, accelerating training and learning,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Durvalumab in Metastatic Adenocarcinoma of The Pancreas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Durvalumab in Metastatic Adenocarcinoma of The Pancreas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Durvalumab in Metastatic Adenocarcinoma of The Pancreas Drug...
-
Product Insights
Mild Cognitive Impairment – Drugs In Development, 2023
Global Markets Direct’s, ‘Mild Cognitive Impairment - Drugs In Development, 2023’, provides an overview of the Mild Cognitive Impairment pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mild Cognitive Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Ischemia Reperfusion Injury – Drugs In Development, 2023
Global Markets Direct’s, ‘Ischemia Reperfusion Injury - Drugs In Development, 2023’, provides an overview of the Ischemia Reperfusion Injury pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ischemia Reperfusion Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Cognitive Impairment – Drugs In Development, 2023
Global Markets Direct’s, ‘Cognitive Impairment - Drugs In Development, 2023’, provides an overview of the Cognitive Impairment pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cognitive Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...